Abstract
Hepatic microsomal cytochrome P450 (CYP) enzymes have broad and overlapping substrate specificity and catalyze a variety of monooxygenase reactions, including aliphatic and aromatic hydroxylations, N-hydroxylations, oxygenations of heteroatoms (N, S, P and I), alkene and arene epoxidations, dehalogenations, dehydrogenations and N-, O- and S-dealkylations. Individual CYP enzymes typically catalyze the oxidative metabolism of a common substrate in a regioselective and stereoselective manner. In addition, different CYP enzymes often utilize different monooxygenase reactions when oxidizing a common substrate. This review examines various oxidative reactions catalyzed by a CYP enzyme acting on a single substrate. In the first example, 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47), a halogenated aromatic environmental contaminant, was oxidatively biotransformed by human CYP2B6. Nine different metabolites of BDE-47 were produced by CYP2B6 via monooxygenase reactions that included aromatic hydroxylation, with and without an NIH-shift, dealkylation and debromination. In the second example, lithocholic acid (3α-hydroxy-5β-cholan-24-oic acid), an endogenous bile acid, served as a substrate for human CYP3A4 and yielded five different metabolites via aliphatic hydroxylation and dehydrogenation reactions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Abbreviations: BDE-47 2,2′,4,4′-tetrabromodiphenyl ether, BDE-99 2,2′,4,4′,5-pentabromodiphenyl ether, CAR constitutive androstane receptor, CYP cytochrome P450, lithocholic acid 3α-hydroxy-5β-cholan-24-oic acid, PBDEs polybrominated diphenyl ethers, PXR pregnane X receptor, QSAR quantitative structure-activity relationship.
References
Burke MD, Mayer RT (1983) Differential effects of phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and cytochrome P-450-binding of phenoxazone and a homologous series of its n-alkyl ethers (alkoxyresorufins). Chem Biol Interact 45:243–258
Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T, Mayer RT (1985) Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem Pharmacol 34:3337–3345
Burke MD, Thompson S, Weaver RJ, Wolf CR, Mayer RT (1994) Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 48:923–936
Jacqz-Aigrain E, Funck-Brentano C, Cresteil T (1993) CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:147–204
Smith HS (2011) The metabolism of opioid agents and the clinical impact of their active metabolites. Clin J Pain 27:824–838
Kharasch ED (2000) Opioid analgesics. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (eds) Metabolic drug interactions. Lippincott Williams & Wilkins, Philadelphia, pp 297–319
Ryan D, Levin W (1990) Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol Ther 45:153–239
Rendic S, Nolteernsting E, Schänzer W (1999) Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. J Chromatogr Biomed Appl 735:73–83
Choi MH, Skipper PL, Wishnok JS, Tannenbaum SR (2005) Characterization of testosterone 11β-hydroxylation catalyzed by human liver microsomal cytochromes P450. Drug Metab Dispos 33:714–718
Rettie AE, Eddy AC, Heimark LD, Gibaldi M, Trager WF (1989) Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos 17:265–270
Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54–59
Trager WF (2000) Oral anticoagulants. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (eds) Metabolic drug interactions. Lippincott Williams & Wilkins, Philadelphia, pp 403–413
Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, Wrighton SA (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286:1253–1259
Ekins S, Wrighton SA (1999) The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 31:719–754
Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF (2004) The structure of human cytochrome P450 3A4 determined by x-ray crystallography to 2.05Å resolution. J Biol Chem 279:38091–38094
Ekroos M, Sjögren T (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A 103:13682–13687
Sevrioukova IF, Poulos TL (2010) Structure and mechanism of the complex between cytochrome P450 3A4 and ritonavir. Proc Natl Acad Sci U S A 107:18422–18427
Dong D, Wu B (2012) Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Drug Metab Rev 44:1–17
Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, Schuetz EG (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307:906–922
Croom EL, Stevens JC, Hines RN, Wallace AD, Hodgson E (2009) Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem Pharmacol 78:184–190
Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295–306
Janmohamed A, Dolphin CT, Phillips IR, Shephard EA (2001) Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. Biochem Pharmacol 62:777–786
Ding X, Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tract. Annu Rev Pharmacol Toxicol 43:149–173
Hoffman SM, Nelson DR, Keeney DS (2001) Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 11:687–698
Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399–415
Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N, Ando M (2003) Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 31:398–403
Honda M, Muroi Y, Tamaki Y, Saigusa D, Suzuki N, Tomioka Y, Matsubara Y, Oda A, Hirasawa N, Hiratsuka M (2011) Functional characterization of CYP2B6 allelic variants in demethylation of antimalarian artemether. Drug Metab Dispos 39:1860–1865
Xu C, Ogburn ET, Guo Y, Dest Z (2012) Effects of the CYP2B6*6 allele on catalytic properties of inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab Dispos 40:717–725
Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222–1230
Mimura M, Baba T, Yamazaki H, Ohmori S, Inui Y, Gonzalez FJ, Guengerich FP, Shimada T (1993) Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab Dispos 21:1048–1056
Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TKH, Waxman DJ (1997) Human cytochrome P450 2B6. Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985–992
Chang TKH, Bandiera SM, Chen J (2003) Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab Dispos 31:7–10
Pascussi JM, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ (2000) Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol Pharmacol 58:1441–1450
Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA (2001) Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60:427–431
Wang H, Faucette SR, Gilbert D, Jolley SL, Suseyoshi T, Negishi M, LeCluyse EL (2003) Glucucorticoid receptor enhancement of pregnane X receptor mediated CYP2B6 regulation in primary human hepatocytes. Drug Metab Dispos 31:620–630
Faucette SR, Zang T-C, Moore R, Sueyoshi T, Omiechinski CJ, LeCluyse EL, Negishi M, Wang H (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320:72–80
Washio I, Maeda M, Sugiura C, Shiga R, Yoshida M, Nonen S, Fujio Y, Azuma J (2011) Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes. Drug Metab Dispos 39:1–3
Mikyss S, Lerman C, Shields PG, Mash DC, Tyndale RF (2003) Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45:122–132
Hodgson E, Rose RL (2007) The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals. Pharmacol Ther 113:420–428
Wang H, Tompkins LM (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 enzyme. Curr Drug Metab 9:598–610
Chang TKH, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629–5637
Styles JA, Davies A, Lim CK, De Matteis F, Stanley LA, White INH, Yuan ZX, Smith LL (1994) Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 15:5–9
Nakajima M, Yamamoto T, Nunoya KI, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212–1217
Hesse LM, Venkatakrishnan K, Court MH, Von Moltke LL, Duan SX, Shader RI, Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176–1183
Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287–300
Mo SL, Liu YH, Duan W, Wei MQ, Kanwar JR, Zhou SF (2009) Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab 10:730–753
Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, Funae Y (1996) Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol 51:1041–1050
Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzalez FJ, Gelboin HV (1997) Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 18:207–214
Tang J, Cao Y, Rose RL, Brimfield AA, Dai D, Goldstein JA, Hodgson E (2001) Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. Drug Metab Dispos 29:1201–1204
Buratti FM, Volpe MT, Meneguz A, Vittozzi L, Testai E (2003) CYP-specific bioactivation of four organophosphorthioate pesticides by human liver microsomes. Toxicol Appl Pharmacol 186:143–154
Buratti FM, D’Aniello A, Volpe MT, Meneguz A, Testai E (2005) Malathion bioactivation in the human liver: the contribution of different cytochrome P450 isoforms. Drug Metab Dispos 33:295–302
Sams C, Cocker J, Lennard MS (2004) Biotransformation of chlorpyrifos and diazinon by human liver microsomes and recombinant human cytochrome P450s (CYP). Xenobiotica 34:861–873
Foxemberg FJ, McGarrigle BP, Knaak JB, Kostinyak PJ, Olson JR (2007) Human hepatic cytochrome P450-specific metabolism of parathion and chlorpyrifos. Drug Metab Dispos 35:189–193
Ellison CA (2012) Human hepatic cytochrome P450-specific metabolism of the organophosphorus pesticides methyl parathion and diazinon. Drug Metab Dispos 40:1–5
Ariyoshi N, Oguri K, Koga N, Yoshimura H, Funae Y (1995) Metabolism of the highly persistent PCB congener, 2,4,5,2′,4′,5′-hexachlorobiphenyl by human CYP2B6. Biochem Biophys Res Commun 212:455–460
Stresser DM, Kupfer D (1999) Monospecific antipeptide antibody to cytochrome P450 2B6. Drug Metab Dispos 27:517–525
Hu Y, Kupfer D (2002) Metabolism of endocrine disruptor pesticide-methoxychlor by human P450s: pathways involving a novel catechol metabolite. Drug Metab Dispos 30:1035–1042
Hu YD, Kupfer D (2002) Enantioselective metabolism of the endocrine disruptor pesticide methoxychlor by cytochromes P450 (P450s): major differences in selective enantiomer formation by various P450 isoforms. Drug Metab Dispos 30:1329–1336
Lee HK, Moon JK, Chang CH, Choi H, Park HW, Park BS, Lee HS, Hwang EC, Lee YD, Liu KH, Kim JH (2006) Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms. Drug Metab Dispos 34:1090–1095
Shou MG, Korzekwa KR, Crespi CL, Gonzalez FJ, Gelboin HV (1994) The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol. Mol Carcinog 10:159–168
Shou MG, Korzekwa KR, Krausz MS, Crespi CL, Gonzalez FJ, Gelboin HV (1994) Regioselective and stereoselective metabolism of phenanthrene by 12 cDNA-expressed human, rodent, and rabbit cytochromes P450. Cancer Lett 83:305–313
Yamazaki H, Mimura M, Oda Y, Gonzalez FJ, El Bayoumy K, Chae YH, Guengerich FP, Shimada T (1994) Activation of trans-1,2-dihydro-6-aminochrysene to genotoxic metabolites by rat and human cytochromes P450. Carcinogenesis 15:465–470
Cho TM, Rose RL, Hodgson E (2006) In vitro metabolism of naphthalene by human microsomal cytochrome P450 enzymes. Drug Metab Dispos 34:176–183
Lewis DFV (1996) Cytochromes P450: structure, function, and mechanism. Taylor & Francis, London
Lewis DFV (2000) On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Toward the prediction of human P450 substrate specificity and metabolism. Biochem Pharmacol 60:293–306
Lewis DFV (2001) Guide to cytochromes P450: structure and function. Taylor & Francis, London
Guengerich FP (2005) Human cytochrome P450 enzymes. In: Otiz de Montellano PR (ed) Cytochrome P450: structure, mechanism, and biochemistry, 3rd edn. Kluwer Academic/Plenum Publishers, New York, pp 377–530
Martignoni M, Groothuis GMM, de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–894
Paine MF, Hart HL, Ludington SS, Haining RL, Retie AE, Zeldin DC (2006) The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 34:880–886
Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, Deglmann CJ, Burk O, Buntefuss D, Escher S, Bishop C, Koebe HG, Brinkmann U, Klenk HP, Kleine K, Meyer UA, Wojnowski L (2001) Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11:111–121
Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Van den Branden M (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207–213
Shimada T, Yamazaki H, Mimura H, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423
Woldbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M, Zamger UM (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978–988
Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755–761
Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumara K, Honda G, Nakagawa K (2004) CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 19:120–129
Wrighton SA, Ring BJ, Watkins RB, Van den Branden M (1989) Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 86:97–105
Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883–891
Daly AK (2006) Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45:13–31
Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016–1023
Lu C, Li AP (2001) Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague–Dawley rat, minipig, and beagle dog. Chem Biol Interact 134:271–281
Wang K, Chen S, Xie W, Wan YJY (2008) Retinoids induce cytochrome P450 3A4 through the RXR/VDR-mediated pathway. Biochem Pharmacol 75:2204–2213
Woodland C, Huang TT, Gryz E, Bendayan R (2008) Expression, activity and regulation of CYP3A in human and rodent brain. Drug Metab Rev 40:149–168
Kliewer SA, Goodwin B, Willson TM (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687–702
Burk O, Wojnowsk L (2004) Cytochrome 3A and their regulation, Naunyn-Schmiedeberg’s Arch. Pharmacology 369:105–124
Nielsen TL, Rasmussen BB, Flinois JP, Beaune P, Brisen K (1999) In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J Pharmacol Exp Ther 289:31–37
Hrycay EG, Bandiera SM (2008) Cytochrome P450 enzymes. In: Gad SC (ed) Preclinical development handbook: ADME and biopharmaceutical properties. Wiley, Hoboken, pp 627–696
Christensen N, Mathiesen L, Postvoll LW, Winther B, Molden E (2009) Different enzyme kinetics of midazolam in recombinant CYP3A4 microsomes from human and insect sources. Drug Metab Pharmacokinet 24:261–268
Maekawa K, Yoshimura T, Saito Y, Fujimura Y, Aohara F, Emoto C, Iwasaki K, Hanioka N, Narimatsu S, Niwa T, Sawada J (2009) Functional characterization of CYP3A4: catalytic activities toward midazolam and carbamazepine. Xenobiotica 39:140–147
Hrycay EG, Bandiera SM (2009) Expression, function and regulation of mouse cytochrome P450 enzymes: comparison with human cytochrome P450 enzymes. Curr Drug Metab 10:1151–1183
Yamazaki H, Shimada T (1997) Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 346:161–169
Feo ML, Gross MS, McGarrigle BP, Eljarrat E, Barcelo D, Aga DS, Olson JR (2013) Biotransformation of BDE-47 to potentially toxic metabolites is predominantly mediated by human CYP2B6. Environ Health Perspect 121:440–446
Erratico CA, Szeitz A, Bandiera SM (2013) Biotransformation of 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47) by human liver microsomes: identification of cytochrome P450 2B6 as the major enzyme involved. Chem Res Toxicol 26:721–731
Alaee M, Arias P, Sjödin A, Bergman A (2003) An overview of commercially used brominated flame retardants, their applications, their use patterns in different countries/regions and possible mode of release. Environ Int 29:683–689
LaGuardia AMJ, Hale RC, Harvey E (2006) Detailed polybrominated diphenyl ether (PBDE) congener composition of the widely used penta-, octa-, and deca-PBDE technical flame-retardant mixtures. Environ Sci Technol 40:6247–6254
Hale RC, LaGuardia MJ, Harvey E, Mainor TM (2002) Potential role of fire retardant-treated polyurethane foam as a source of brominated diphenyl ethers to the US environment. Chemosphere 46:729–735
Hites RA (2004) Polybrominated diphenyl ethers in the environment and in people: a meta-analysis of concentration. Environ Sci Technol 38:945–956
Darnerud PO, Eriksen GS, Jóhannesson T, Larsen PB, Viluksela M (2001) Polybrominated diphenyl ethers: occurrence, dietary exposure, and toxicology. Environ Health Perspect 109:49–68
Hale RC, La Guardia MJ, Harvey EP, Mainor TM, Duff MH, Gaylor MO (2001) Polybrominated diphenyl ether flame retardants in Virginia freshwater fishes (USA). Environ Sci Technol 35:4585–4591
Ikonomou M, Rayne S, Addison RF (2002) Exponential increase of brominated flame retardants, polybrominated diphenyl ethers, in the Canadian arctic from 1981 to 2000. Environ Sci Technol 36:1886–1892
Stapleton HM, Dodder NG, Offenberg JH, Schantz MM, Wise SA (2005) Polybrominated diphenyl ethers in house dust and clothes dryer lint. Environ Sci Technol 39:925–931
de Wit CA, Alaee M, Muir DCG (2006) Levels and trends of brominated flame retardants in the Arctic. Chemosphere 64:209–233
Gómara B, Herrero L, Ramos JJ, Mateo JR, Fernandez MA, Garcia JF, Gonzales MJ (2007) Distribution of polybrominated diphenyl ethers in human umbilical cord serum, paternal serum, maternal serum, placentas, and breast milk from Madrid population, Spain. Environ Sci Technol 41:6961–6968
Kelly BC, Ikonomou MG, Blair JD, Gobas FAPC (2008) Bioaccumulation behaviour of polybrominated diphenyl ethers (PBDEs) in a Canadian Arctic marine food web. Sci Total Environ 401:60–72
Vonderheide AP, Mueller KE, Meija J, Welsh L (2008) Polybrominated diphenyl ethers: causes of concern and knowledge gaps regarding environmental distribution, fate and toxicity. Sci Total Environ 400:425–436
Athanasiadou M, Cuadra SN, Marsh G, Bergman A, Jakobsson K (2008) Polybrominated diphenyl ethers (PBDEs) and bioaccumulative hydroxylated PBDE metabolites in young humans from Managua, Nicaragua. Environ Health Perspect 116:400–408
Sjödin A, Wong L-Y, Jones RS, Park A, Zhang Y, Hodge C, Dipietro E, McClure C, Turner W, Needham LL, Patterson DG Jr (2008) Serum concentrations of polybrominated diphenyl ethers (PBDEs) and polybrominated biphenyl (PBB) in the United States population: 2003–2004. Environ Sci Technol 42:1377–1384
Stapleton HM, Sjödin A, Jones RS, Niehuser S, Zhang Y, Patterson DG (2008) Serum levels of polybrominated diphenyl ethers (PBDEs) and foam recyclers and carpet installers working in the United States. Environ Sci Technol 42:3453–3458
Daniels JL, Pan I-J, Jones R, Anderson S, Patterson DG Jr, Needham LL, Sjödin A (2010) Individual characteristics associated with PBDE levels in U.S. milk samples. Environ Health Perspect 118:155–160
Örn U, Klasson-Wehler E (1998) Metabolism of 2,2′,4,4′-tetrabromodiphenyl ether in rat and mouse. Xenobiotica 28:199–211
Marsh G, Athanasiadou M, Athanassiadis XJ, Sandholm A (2006) Identification of hydroxylated metabolites in 2,2′,4,4′-tetrabromodiphenyl ether exposed rats. Chemosphere 63:690–697
Sanders JM, Chen LJ, Lebetkin EH, Burka LT (2006) Metabolism and disposition of 2,2′,4,4′- tetrabromodiphenyl ether following administration of single or multiple doses to rats and mice. Xenobiotica 36:103–117
Staskal DF, Hakk H, Bauer D, Diliberto JJ, Birnbaum LS (2006) Toxicokinetics of polybrominated diphenyl ether congeners 47, 99, 100, and 153 in mice. Toxicol Sci 94:28–37
Hamers T, Kamstra JH, Sonneveld E, Murk AJ, Visser TJ, Van Velzen MJ, Brouwer A, Bergman A (2008) Biotransformation of brominated flame retardants into potentially endocrine-disrupting metabolites, with special attention to 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47). Mol Nutr Food Res 52:284–298
Erratico CA, Moffatt SC, Bandiera SM (2011) Comparative oxidative metabolism of BDE-47 and BDE-99 by rat liver microsomes. Toxicol Sci 123:37–47
Lupton SJ, McGarrigle BP, Olson JR, Wood TD, Aga DS (2009) Human liver microsome-mediated metabolism of brominated diphenyl ethers 47, 99, and 153 and identification of their major metabolites. Chem Res Toxicol 22:1802–1809
Lupton SJ, McGarrigle BP, Olson JR, Wood TD, Aga DS (2010) Analysis of hydroxylated polybrominated diphenyl ether metabolites by liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 24:2227–2235
Marteau C, Chevolleau S, Jouanin I, Perdu E, De Sousa G, Rahmani R, Antignac JP, LeBizec B, Zalko D, Debrauwer L (2012) Development of a liquid chromatography/atmospheric pressure photo-ionization high resolution mass spectrometry analytical method for the simultaneous determination of polybrominated diphenyl ethers and their metabolites: application to BDE-47 metabolism in human hepatocytes. Rapid Commun Mass Spectrom 26:599–610
Moffatt S, Edwards PR, Szeitz A, Bandiera SM (2011) A validated liquid chromatography-mass spectrometry method for the detection and quantification of oxidative metabolites of 2,2′,4,4′-tetrabromodiphenyl ether in rat hepatic microsomes. Am J Anal Chem 2:352–362
Erratico CA, Szeitz A, Bandiera SM (2010) Validation of a novel in vitro assay using ultra performance liquid chromatography-mass spectrometry (UPLC/MS) to detect and quantify hydroxylated metabolites of BDE-99 in rat liver microsomes. J Chromatogr B 878:1562–1568
Korzekwa KR, Swinney DC, Trager WT (1989) Isotopically labeled chlorobenzenes as probes for the mechanism of cytochrome P-450 catalyzed aromatic hydroxylation. Biochemistry 28:9019–9027
de Visser S, Shaik S (2003) A proton-shuttle mechanism mediated by the porphyrin in benzene hydroxylation by cytochrome P450 enzymes. J Am Chem Soc 125:7413–7424
Erratico CA, Szeitz A, Bandiera SM (2012) Oxidative metabolism of BDE-99 by human liver microsomes: predominant role of CYP2B6. Toxicol Sci 129:280–292
Ortiz de Montellano PR (1995) Oxygen activation and reactivity. In: Ortiz de Montellano PR (ed) Cytochrome P450: structure, mechanism, and biochemistry, 2nd edn. Plenum Press, New York, pp 245–304
Deo AK, Bandiera SM (2009) 3-Ketocholanoic acid is the major in vitro human hepatic microsomal metabolite of lithocholic acid. Drug Metab Dispos 37:1938–1947
Chiang JY (2004) Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol 40:539–551
Makishima M (2005) Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J Pharmacol Sci 97:177–183
Kalaany NK, Mangelsdorf DJ (2006) LXRs and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 68:159–191
Chiang JY (2009) Bile acids: regulation of synthesis. J Lipid Res 50:1955–1966
Nguyen A, Bouscarel B (2008) Bile acids and signal transduction: role in glucose homeostasis. Cell Signal 20:2180–2197
Fiorucci S, Mencarelli A, Palladino G, Cipriani S (2009) Bile acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 30:570–580
Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P (2009) Bile acids as regulatory molecules. J Lipid Res 50:1509–1520
Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89:147–191
Hofmann AF (1999) Bile acids: the good, the bad, and the ugly. News Physiol Sci 14:24–29
Hofmann AF (1999) The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 159:2647–2658
Hofmann AF, Hagey LR (2008) Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 65:2461–2483
Dawson PA, Schneider BL, Hofmann AF (2006) Bile formation and the enterohepatic circulation. In: Johnson LR (ed) Physiology of the gastrointestinal tract, vol 1, 4th edn. Academic, New York, pp 1437–1462
Small DM (2003) Role of ABC transporters in secretion of cholesterol from liver into bile. Proc Natl Acad Sci U S A 100:4–6
Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537–592
Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter DL, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to complete absence of phospholipid from bile and to liver disease. Cell 75:451–462
Lehman-McKeeman LD (2008) Absorption, distribution, and excretion of toxicants. In: Klaassen CD (ed) Casarett & Doull’s toxicology: the basic science of poisons, 7th edn. McGraw Hill, Toronto, pp 131–159
Leuschner U (2009) Formation and secretion of bile and bilirubin metabolism. In: Dancygier H (ed) Clinical hepatology: principles and practice of hepatobiliary diseases, vol 1. Springer, Berlin, pp 103–126
Grober J, Zaghini I, Fujii H, Jones SA, Kliewer SA, Willson TM, Ono T, Besnard P (1999) Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J Biol Chem 274:29749–29754
Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B (1999) Identification of a nuclear receptor for bile acids. Science 284:1362–1365
Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102:731–744
Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, Kliewer SA, Gonzalez FJ (2007) Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 48:2664–2672
Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 98:3369–3374
Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ (2002) Vitamin D receptor as an intestinal bile acid sensor. Science 296:1313–1316
Hofmann AF (2002) Cholestatic liver disease: pathophysiology and therapeutic options. Liver 22(Suppl 2):14–19
Ridlon JM, Kang DJ, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47:241–259
Setchell KD, Rodrigues CM, Clerici C, Solinas A, Morelli A, Gartung C, Boyer J (1997) Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 112:226–235
Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R, Zatloukal K, Jaeschke H, Denk H, Trauner M (2006) Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol 168:410–522
Beilke LD, Besselsen DG, Cheng Q, Kulkarni S, Slitt AL, Cherrington NJ (2008) Mininal role of hepatic transporters in the hepatoprotection against LCA-induced intrahepatic cholestasis. Toxicol Sci 102:196–204
Deo AK, Bandiera SM (2008) Biotransformation of lithocholic acid by rat hepatic microsomes: metabolite analysis by liquid chromatography/mass spectrometry. Drug Metab Dispos 36:442–451
Wood AW, Swinney DC, Thomas PE, Ryan DE, Hall PF, Levin W, Garland WA (1988) Mechanism of androstenedione formation from testosterone and epitestosterone catalyzed by purified cytochrome P-450b. J Biol Chem 263:17322–17332
Swinney DC, Ryan DE, Thomas PE, Levin W (1988) Evidence for concerted kinetic oxidation of progesterone by purified rat hepatic cytochrome P-450 g. Biochemistry 27:5461–5470
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Erratico, C.A., Deo, A.K., Bandiera, S.M. (2015). Regioselective Versatility of Monooxygenase Reactions Catalyzed by CYP2B6 and CYP3A4: Examples with Single Substrates. In: Hrycay, E., Bandiera, S. (eds) Monooxygenase, Peroxidase and Peroxygenase Properties and Mechanisms of Cytochrome P450. Advances in Experimental Medicine and Biology, vol 851. Springer, Cham. https://doi.org/10.1007/978-3-319-16009-2_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-16009-2_5
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-16008-5
Online ISBN: 978-3-319-16009-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)